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ABSTRACT 
 
THE ESTIMATED COST OF THE PROVIDER’S RECOMMENDED FOLLOW-UP 
INTERVAL VISITS ON PATIENTS WITH CONTROLLED HYPERTENSION AT 
TEACHING CITY HOSPITAL 
 
By 
 
AGNESS MCHOME 
 
APRIL 2020 
 
Background:  
Although the prevalence, treatment, and control of hypertension are well documented in the 
US, the medical annually costs of visits associated with controlled hypertension in local 
institutions and factors affecting the medical costs are not well studied. This study is designed 
to analyze the annual cost of visits for controlled hypertension treatment in the Primary Care 
Center at Grady Hospital in 2016-2017.   
 
Methods: 
Data (2016-17) were obtained from a retrospective chart review of all subjects with 
hypertension and diabetics using randomly selected providers in the Primary Care Center at 
Grady Hospital. Controlled hypertension was defined as all patients with blood pressure 
<140/90mmhg. Costs of visits were obtained from the. Medicare fee schedule (2016), and 
published literature. Univariate and multivariate regression analyses were used to determine 
odds of spending more on hypertension visits. In the multivariate analyses adjustments were 
made for age, sex, ethnicity, other comorbidities, acute issue, and having diabetics. 
 
Results:  
Seven hundred and twenty-five subjects from a sample of 835 were found to have controlled 
hypertension. Total per-person annual costs of treatment associated with controlled 
hypertension ranged from $ 102.98 to $411.92 in 2016-2017. Age of the participants, other 
comorbidities, more than one acute issue and, having diabetes were found to be the reasons for 
variation in annual costs of visits for hypertensive patients. Controlling for other clinical and 
demographic characteristics, patient’s annual cost of visits differs among provider’s level of 
training(p=0.001).  
 
Conclusion:  
Variations in annual costs of visits among several groups of hypertensive patients have been 
observed. Expansion of preventive services for other health issues that are associated with 
hypertension may be an effective way to alleviate the economic burden from the individual and 
national level.    
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Chapter I-Introduction 
1.1 Background 
Chronic diseases, such as hypertension, diabetes, and cancer are the primary cause of 
morbidity, disability, and mortality worldwide. Hypertension causes an estimated 7.5 million 
deaths, about 12.8% of the total of all deaths globally [1,2]. It can lead to other health conditions 
and death. Health outcomes of hypertension may include Coronary artery disease, heart attack, 
congestive heart failure, stroke, kidney damage, vision loss, and erectile dysfunction in males. 
It is also one of the leading causes of mortality and mortality in the United States. According 
to the National Vital Statistics 2017 report, there are approximately 67 million adults who have 
hypertension, and deaths related to hypertension increased by 0.4% from the 2016 rate. [3]. 
Furthermore, it is estimated that the prevalence of hypertension will increase by more than 9%, 
or approximately 27 million additional people, from 2010 to 2030 [4]. Hypertension is a crucial 
public health problem that continues to be on the rise.  
Hypertension requires regular long-term follow-up as a standard of medical care. About 
one-third of the primary care visits per year in the US are for follow up on chronic diseases 
such as hypertension (HTN) and Diabetic Mellitus (DM) [3]. Current guidelines recommend 
that patients be followed up within a month when high blood pressure is noted. Also, guidelines 
recommend follow-up intervals for patients with controlled hypertension be seen for regular 
follow-up at an interval of 3 to 6 months [5]. However, different literature shows that the 
intervals between provider-patient encounters are substantially longer than the recommended 
by guidelines.  
The increasing prevalence of hypertension, hypertension follow-up visits, and 
hypertension-related health conditions continue to drive the cost of treatment upwards.  In 
2010, the Agency for Healthcare Research and Quality (AHRQ) reported that the direct medical 
expenditures related to hypertension rose from $42.9 billion nationwide per year to 45 billion 
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in direct medical costs in 2011 and medical expenditure due to primary care visits was 
estimated to be a $13.04 billion [6,7]. Increased concern regarding access to care combined 
with increasing pressure to curb healthcare costs has prompted health professionals to think 
about how best to manage chronic diseases. Evidence-based follow-up intervals have the 
potential to reduce healthcare costs per person and improve access without compromising or 
restricting care. 
Hypertension is even more prevalent in high‐ risk populations (i.e., low‐ income 
patients, African Americans etc.) who tend to receive care at Primary health care centers [8]. 
Although trends in prevalence, treatment, and control of hypertension have been documented, 
costs associated with visits for hypertensive patients at primary care centers have not yet been 
evaluated. Thus, this project was serving as formative research to ascertain valid policy 
measures that will help develop local guidelines for recommended follow-up for patients with 
controlled hypertension in the primary care center for potential reduction of follow-up 
frequency, which will subsequently reduce the costs of treatment without compromising the 
outcome. 
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1.2 Research Aim  
This main research objective is to estimate the costs of treatment for follow up visits for 
controlled hypertensive patients at the Primary Care Center at Grady. In order to achieve that 
broader objective, the researcher applied a retrospective chart review of all encounters for 
hypertensive of the randomly selected providers at the Primary Care Center at Grady Hospital 
from July 1St 2016 through June 30, 2017.  Other specific objectives are:  
 To estimate the annual cost of visits for recommended follow-up by providers for 
controlled HTN at the Primary Care Center at Grady.  
 To investigate whether the annual costs of visits for controlled HTN differ among 
faculty and postgraduate resident students. 
  To investigate factors that are associated with the difference in annual costs of visits 
treatment for controlled HTN 
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Chapter II-Literature Review 
Hypertension defined  
The 2016 American College of Cardiology/American Heart Association (ACC/AHA) 
Guideline for diagnosis and management of hypertension in adults provided updated blood 
pressure thresholds for defining hypertension and for the initiation of and goals of 
pharmacologic treatment of hypertension [9] This guideline, redefined hypertension as systolic 
BP ≥140 mm Hg or diastolic BP ≥90 mm Hg. The guideline further explains that the 2016 
Guideline for High Blood Pressure in Adults Normal BP is defined as <120-129/<80-84 mm 
Hg; high normal BP 130-139/<85-89 mm Hg; hypertension grade 1 is 140-159/90-99-mm Hg, 
and hypertension grade 2 (moderate) 2 is ≥160-179/100-109 ≥9 mm Hg; grade 3 (severe) 
hypertension ≥180 and or ≥110 mmHg and Isolated systolic hypertension >140 and <90. These 
recommendations were based mainly on observational data reporting a linear association 
between BP and coronary heart disease, stroke, and death, even with BP levels as low as 120-
129/80-89 mm Hg, [10,11,12] as well as the Systolic Blood Pressure Intervention Trial 
(SPRINT) which reported a reduction in major cardiovascular events with an intensive systolic 
BP target less than 120 mm Hg compared with less than 140 mm Hg. 
 
CAUSES OF HYPERTENSION: 
Genetic predisposition:  
Genes likely play some role in high blood pressure, heart disease, and other related conditions. 
However, it is also likely that people with a family history of high blood pressure share typical 
environments and other potential factors that increase their risk. A combination of hereditary 
and unhealthy lifestyle may increase the risk of hypertension. [13]. CDC's Office of Public 
Health Genomics, Surgeon General, and other federal agencies developed a web-based tool to 
help families learn about their risk for hypertension that can run in families. 
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Environmental Risk Factors: 
Various environmental exposures, like diet, physical activity, and alcohol consumption, 
influence high blood pressure. Many dietary components have been associated with high Blood 
pressure [14,15]. Other factors are diet-related associated with high blood pressure, including 
overweight and obesity, excess sodium intake, insufficient intake of potassium, calcium, 
magnesium, protein fiber, and fish fats. A combination of poor diet, physical inactivity, and 
alcohol intake is the underlying cause of a large proportion of hypertension. 
 
Childhood Risk Factors and Hypertension Tracking.  
Studies investigating the association between childhood high blood pressure and adult high 
blood pressure showed a correlation in the prediction of hypertension in adulthood [16].  With 
the inclusion of genetic factors and childhood obesity, premature birth has been associated with 
hypertension in adulthood, affecting mostly women [17,18,19]. Children with cardiovascular 
disease risk factors like high blood pressure, obesity, and diabetes, are more likely to have heart 
disease and stroke as adults. 
 
HYPERTENSION AND CARDIOVASCULAR RISKS; 
Hypertension has been associated with the risk factor for premature cardiovascular diseases 
[20], such as myocardial infarction and cerebrovascular diseases such as ischemic or 
hemorrhagic stroke.  In addition to that, hypertension may lead to kidneys and eye 
complications. A cohort study of consisted of 1,316,363 participants, with 36,784,850 blood-
pressure measurements examining the effects of systolic blood pressure and diastolic blood 
pressure independently found that high risk of myocardial infarction, ischemic stroke, or 
hemorrhagic stroke in both the lowest and highest deciles was high in diastolic blood pressure 
[21]. Although it has been proven that though systolic blood pressure indeed had a more 
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significant effect, systolic and diastolic blood pressures, each independently influenced 
cardiovascular outcomes, and therefore diastolic blood pressure ought not to be ignored. 
 
HYPERTENSION STATISTICS IN THE US:  
A cross-sectional study of a national representative sample of the noninstitutionalized civilian 
US population from the National Health and Nutrition Examination Survey (NHANES) 1999–
2016 conducted by the National Center for Health Statistics (NCHS) of the US Centers for 
Disease Control and Prevention found that the total burden of hypertension has consistently 
increased [22]. However, the same report showed that there had been an improvement in 
hypertension prevalence from 1999 to 2016 among individuals aged ≥60 years, but not among 
other age groups. According to CDC, about half of adults in the United States (108 million, or 
45%) have hypertension defined as a systolic blood pressure ≥ 130 mm Hg or a diastolic blood 
pressure ≥ 80 mm Hg or are taking medication for hypertension [23]. Additionally, in 2017 
hypertension contributes to nearly half of million deaths in the United States. 
 
HYPERTENSION MANAGEMENT AND TREATMENT:  
The US Preventive Services Task Force and the American Academy of Family Physicians' 
hypertension screening are highly recommended to adults of age 18 and above to ensure a 
thorough insight into the health of even the most seemingly well individual [24]. When 
diagnosed with high blood pressure, a change of lifestyle is highly recommended; otherwise, 
drug therapy is needed. First-line medications used in the treatment of hypertension include 
diuretics, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers 
(ARBs), beta-blockers, and calcium channel blockers (CCBs) [25]. Some patients will require 
two or more antihypertensive medications to achieve their BP targets. In newly diagnosed 
patients with BP>20/10 mm Hg above goal [,26], antihypertensives or a combination 
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hypertensive may be added immediately. It is recommended that for side effects minimization, 
a second drug with a complementary mechanism of action should be added before the initial 
drug is used in the maximum recommended dosing. 
 
HYPERTENSION TREATMENT COSTS.  
In 2010, about 58.6 million persons or 25.1 percent of adults age 18 and older were treated for 
hypertension. Direct medical spending to treat hypertension totaled $42.9 billion in 2010, with 
almost half ($20.4 billion) in the form of prescription medications. Annual expenditures for 
those treated for hypertension averaged $733 per adult in 2010. [7]. The burden of treatment 
for people with hypertension also exceeds those without the disease. It was estimated that US 
adults with hypertension spend around $2000 more than those without hypertension [29]. 
Proper action to curb the costs should be taken to reduce public burden. 
 
HYPERTENSION TREATMENT AT THE PRIMARY CARE CENTER AT GRADY 
 
The Primary Care Center at Grady is the largest outpatient diabetes center in the Southeast, 
providing world-class diabetes care and education, one of the hypertensions and diabetics clinic 
serving the DeKalb and Fulton County residents. Routine medical follow-up for hypertensive 
patients is one of the services provided by faculties and Postgraduates medical residents, 
doctors in training for General Medicine. Estimating what might cost the patient to maintain 
their blood pressure level is essential for the policymaking and other public institutions. Could 
potentially benefit from having a target number of visits.  
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Chapter III-Methodology 
3.1 Data Source and Sample:  
A retrospective chart review of all encounters for hypertension and diabetic Mellitus of the 
randomly selected providers in the Primary Care Center at Grady Hospital from July 1St 2016 
through June 30, 2017, was obtained to explore the cost of provider's recommended follow-up 
interval on patients with Hypertension at the Primary Care Center.  Providers were randomly 
selected from the three clinics and Faculty practice from the Emory Primary Health primary 
that runs on Mondays, Wednesdays, Thursdays, and Fridays. Information on all patient's visits, 
patients' blood pressure level, provider's level of postgraduate training, and other demographic 
characteristics were obtained from the outpatient return visits at the Primary Care Center at 
Grady.  The cost of visits was determined using the 2016 Medicare fee schedule.  A comparison 
was made from the extracted literature form other similar studies.  Patients with uncontrolled 
blood pressure will be excluded from the study (>140/90mmhg) and not well-documented were 
excluded because they need more frequent follow-up and will potentially engender reverse 
causality. 
 
3:2 Eligibility Criteria:  
All hypertensive patients with controlled blood pressure (< 140/90mmhg) who attended the 
Primary Care Center at Grady for the period of July 1St 2016, through June 30, 2017, for follow-
up. 
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3:3 Dependent and primary independent variables. 
 
The dependent variable of this study was the cost of a visit for controlled hypertension 
determined by using the 2016 Medicare fee schedule from the Center for Medicare and Medical 
Aid physician fee schedule. .The primary independent variable was providers' level of training: 
divided into Postgraduate Students Year 1 (PGY 1), year 2 (PGY 2), year 3 (PGY 3), and 
Faculty (PGY 4).  In order to examine the unbiased association between the estimated cost of 
hypertension treatment and the provider’s level of training, the following covariates were 
included in this study.  
 
● Age was reported as the age in years of the participants at the time of the study. Subjects 
were distributed into five age categories: <40, 41 -50, 51-60, 61-70, 71 and above. 
 
● The gender of the research participants was disaggregated as self-reported at the time 
of the hospital visit and was recorded as either male or female. 
 
● Ethnicity/Race was coded into four categories: 1) African American 2) Caucasian 3) 
Hispanics 4) Others. The “Hispanic” category combined Mexican American and other 
Hispanic populations as one group, while the “Other” category combined multi-racial 
and other populations into one group.  
 
● Insurance status of the participants was reported as Centers for Medicare and Medicaid 
Services (CMS), private, others or none. Insurance information of the participants was 
self-reported during their visits and obtained from a retrospective study from July 1, 
2016, through June 30, 2017. 
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● Other patient’s medical conditions including diabetes, BMI, other comorbidities, acute 
issues at the time of the visit, systolic and diastolic blood pressure, and whether the 
patient had both hypertension and diabetes was incorporated in the study because they 
may influence overall health cost of treatment by adding up numbers of hospital visits.  
 
 
3.4: Statistical Analysis 
Statistical Analysis System SAS® (SAS Institute Inc, Cary, NC, USA) software program 
version 9.4 was used for all data analyses. In the descriptive analysis, the frequency and means 
procedure was performed to provide the distribution of various demographic and clinical 
characteristics of the independent variables and covariates. Means procedure was used to 
calculate the annual range cost of hypertension visits.  
The univariate statistical analysis procedure was used to determine factors that are associated 
with the difference in annual costs of visits treatment for controlled HTN at the Primary Care 
Center at Grady. Multivariate logistic regression analysis was performed, and the Wald test 
was used at an alpha level of 0.05 to determine if there is a significant difference in costs of 
treatment annually for controlled hypertensive patients when visiting either postgraduate 
medical residents or Faculty members at 95% Confidence interval (CI) controlling for other 
demographic and clinical characteristics of the patients.   
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Chapter IV-Results 
4.1: Descriptive Statistics 
Descriptive statistics were used to analyze participant characteristics of the sample population. 
The basic demographic and clinical characteristics of the sample population with controlled 
hypertension are shown in Table 1. Between July 1, 2016, through June 30, 2017, a total of 835 
respondents, of whom 725 (86.83 %) had controlled hypertension, attended the Primary Care 
Center at Grady.  In the Sample, 489 (67%) of participants were female, while 236 (32.5%) of 
the remaining individuals were male. Black individuals accounted for 89.9% (N=652) of the 
cases, versus 3.9% of Caucasians, and 4.8% (N=35) were Hispanic. Among controlled 
hypertensive patients, 75.9 % (N=550) had diabetes compared to 24.1% (N=175) of those who 
did not have diabetes. Total per-person annual costs of visits associated with controlled 
hypertension ranged from $ 102.98 to $ 411.92 between 2016-2017.  
 
Table 2 shows the demographic and clinical characteristics of the sample population stratified 
by provider’s level of training. Hypertensive patients who were seen by faculty members and 
postgraduate medical residents had age range 56.3   ± 59.5 for PGY1, 57.7 ± 60.6 for PGY2, 
58.8 ± 61.8 for PGY 3, 59.1 ± 60.7 for faculty members. Patients had at least two comorbidities 
other than diabetes, had diabetics and acute issues. Ethnicity, body mass index, sex, AIC, POCT 
results, Acute Issues, diastolic, and systolic blood pressure were statistically significant (p= 
<.0001) across four levels of education.  
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4.2: Univariate Analysis 
Results revealed a statistically significant difference between the annual cost of a visit for 
controlled hypertension patients and some of the participants' demographic and clinical 
characteristics (Table 2). Individuals who had diabetes were 2 (5%Cl:1.1-2.3) times more likely 
to pay more on visits annually when compared to their non-diabetic counterparts. Age (>40 
years) showed an increased odd of paying more on visits annually on hypertension management 
with an odds ratio of 3.1 (95%Cl:1.5-6.2). Other age categories showed a decreased odd of 
spending more than the national average costs of hypertension treatment. Participants with 
comorbidities who had controlled hypertension were 3.6(95%CI: 1.5-8.4) times more likely to 
pay more on visits annually on treatment when compared to the referenced “No” group. When 
using more than one acute issue as a predictor of paying more on visits annually, individuals 
who had more than one acute issue had an odds ratio 2.7 (95%Cl:1.9-3.8 and level of training, 
sex, insurance status did not show any statistical significance. 
 
4.3: Multivariate Analysis 
Table 3 shows the multivariable analysis of the association between the participants' 
characteristics and the annual cost of visits for controlled hypertension treatment. After 
adjusting for age, gender, insurance status, diabetics, acute issues, comorbidities, and ethnicity, 
provider level of postgraduate level, PGY 2, showed indication of 2.4 increased odds 
(95%Cl:1.9-9.0, p=0.001) of the difference in annual costs of visits for controlled HTN among 
faculty and postgraduate resident students. Comorbidities other than diabetes, odds ratio= 6.0 
(95%Cl:1.2-20.1, p=0.0002) showed indication of an increased odds of the difference in annual 
costs of visits for controlled HTN among faculty and postgraduate resident students when 
compared to individuals who had no comorbidities. Diabetics, odds ratio= 2.0 (95%Cl:1.1-2.3) 
showed an indication of an increased odds of the difference in annual costs of visits for 
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controlled HTN among faculty and postgraduate resident students when compared to their non-
diabetic counterparts. Similarly, acute issues OR=6.0 (95%Cl:1.2-20.1, p=0.0002) indicated an 
increased odd of the difference in annual costs of visits for controlled HTN among faculty and 
postgraduate resident students when compared to an individual who had no acute issues.  
 
 
Chapter V-Discussion 
5.1: Discussion:  
The purpose of this research was to estimate costs of visit for controlled hypertensive 
patients at the Primary Care Center at Grady using a retrospective chart review of all encounters 
for hypertensive and diabetic patients of the randomly selected providers in the Primary Care 
Center at Grady Hospital from July 1St 2016 through June 30, 2017. Overall the results of the 
study suggest that there is variation in the annual cost of visits for hypertension treatment. 
Multivariate analysis revealed that they might be visiting the clinic more often due to pre-
existing conditions like the presence of other diseases such as diabetes, age, and acute 
conditions. This study also shows that hypertension-related health costs rise as the age of the 
person (2.3 (95%Cl:1.5-3.6). Variation in costs of payment was observed between patients who 
visited providers with different levels of education. The results showed that the annual per-
person annual cost of treatment for control hypertension ranged from $102.98 - $411.92.  
Most studies estimating the cost of treatment for hypertensive patients focus on national 
surveys instead of local institutions. A similar study conducted in 2011 found that the annual 
recommended care costs for visits were $177 annually, a slight difference from what this study 
estimated [28]. The difference could be explained by the difference in Medicare and Medicaid 
charged for visits. Additionally, consistent with findings in this study, the study explained that 
there was variation in the costs of visits that could be explained by the severity of hypertension 
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and the presence of other illnesses. Another study focusing on the annual hospital outpatient 
cost of treatment in 2018 also found that the incremental cost of outpatient treatment was 
mainly caused by individual comorbid conditions [29]. Additionally, as adults live longer with 
hypertension, they are likely to be diagnosed with other comorbid illnesses, such as congestive 
heart failure or renal disease. 
 
5.2: Strengths and Limitations 
The study herein provides updated estimates of the costs of visits at the health facility level and 
demonstrate the reasons for variation in costs of visits. The study used the physician fee 
schedule search from the Centers for Medicare & Medicaid services for the year 2016 for a 
more accurate cost of a visit for the Atlanta area. Additionally, the study used actually 
recommended visits by providers for controlled hypertension patients making an estimation of 
the cost of treatment more accurate. Despite these notable strengths, we did not have 
information on medications, emergency visits, inpatient costs, and other services for 
outpatients’ visits for a broader evaluation of costs of treatment  
 
5.3: Implication:  
Provider level of training PGY 2, showed an indication of 2.4 increased odds (95%Cl:1.9-9.0, 
p=0.003) of spending more than the national annual average cost of hypertension management 
(Table 4). Costs of hypertension treatment vary substantially across patients within each 
outcome category. 
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5.4: Conclusion and Future Recommendations:  
The ultimate solution to reduced medical care costs in cutting down unnecessary visits to the 
doctor, especially for people with uncontrolled hypertension. Addressing this problem should 
be tailored through educating health providers on the importance of reduced unnecessary 
hospital visits, especially for patients with controlled hypertension and without any other 
underlying health problems. In order to implement effective hypertension management or 
behavioral change interventions to keep their blood pressure under control. Understanding 
these variations in the group of patients who spend more on keeping their blood pressure level 
under control is of utmost importance. Expansion of preventive and treatment services for other 
health issues that are associated with hypertension may be an effective way to alleviate the 
economic burden from the individual and national level It is essential to identify effective 
interventions and investigate reasons for paying more than the national average cost of 
hypertension treatment when visiting on PGY 2 providers to improve hypertension and cost-
effectively prevent hypertension complications.  
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Tables 
Table 1: Patients demographics and Clinical Characteristics of Study Population with 
Controlled Hypertension at Emory Primary Health Center at Grady, 2016-2017 
 
Patients demographics  N (%) 725= (86.8) 
Age  
       <40 
       41-50 
       51-60 
       61-70 
        >70 
 
 
35(4.8) 
92(12.7) 
243(33.5) 
235(32.4) 
120(16.6) 
Sex 
   Female 
   Male  
 
489(67.5) 
236(32.5) 
Ethnicity 
   Black 
   Caucasian 
   Hispanic 
   Other 
 
652(89.9) 
28(3.9) 
35(4.8) 
10(1.4) 
Insurance 
  None 
  CMS 
  Private 
 
 
223(30.8) 
381(52.6) 
121(16.7) 
 
Providers 
  Faculty 
  PGY1 
  PGY2 
  PGY3 
 
10 
183(32.1) 
212(37.2) 
175(30.7 
Diabetic patients 
   Yes 
    No 
 
 
550(75.9) 
175(24.1 
 
Comorbidities 
    Yes 
     No 
      Missing 
 
690(95.2) 
21(2.9) 
14(1.9) 
 
Cost of treatment 
 
$102.98 - $ 411.92 
      Abbreviations: 
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PGY 1Postgraduate year 1 
PGY 2 Postgraduate year 2 
PGY 3 Postgraduate year 3 
Bold Annual per person cost of hypertension treatment (range) 
Table 2. Basic Clinical and demographic characteristics of the study population: 
 
Variable PGY 1 (n=12) PGY 2 (n=12) PGY 3 (n=12) Faculty (n=10) P-value 
Age (years) 56.3   ± 59.5  57.7 ± 60.6 58.8 ± 61.8 59.1 ± 60.7 <.0001 
A1C 7.1± 12.1 7.3 ± 7.5 6.9 ± 7.5  5.9 ± 11.3 <.0001 
Diabetics  0.7 ± 0.8 0.7 ± 0.8 0.7 ± 0.8 0.7 ± 0.8 <.0001 
POCT results  67.3 ± 117.5 78.8 ± 113.9 69.5 ± 108.1 68.5 ± 108.7 <.0001 
Comorbidities 1.8 ± 1.9  1.8 ± 1.9 1.8 ± 2.0 1.9 ± 2.0 <.0001 
Acute Issues 0.4 ± 0.6 0.3 ± 0.6 0.3 ± 0.5 0.4 ± 0.6 <.0001 
Body mass index (kg m-2) 30.2 ± 79.53 27.4 ± 52.3  29 ± 63.3 36.0 ± 55.7 <.0001 
Diastolic blood pressure (mmHg) 74.89 ± 78.1 73.4 ± 76.4 74.6± 77.3  74.2± 75.2 <.0001 
Diastolic blood pressure (mmHg) 131.4 ± 137.4 130.2 ± 134.1 132 ± 137.2 132.2 ± 134.7 <.0001 
Both diabetes and hypertension 0.5 ± 0.8 0.6 ± 0.7 0.5 ± 0.7 0.6 ± 0.7 <.0001 
      
 
Abbreviations: 
A1C Test used to diagnose type2 and 2 diabetics 
POCT Point of Care Testing 
PGY 1Postigraduate year 1 
PGY 2 Postgraduate year 2 
PGY 3 Postgraduate year 3 
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Table 3. Univariable analysis for the costs of visits and other demographic and clinical 
characteristics for controlled hypertension.  
 
Participants Characteristics OR (95% CL) 
Postgraduate year 
    PGY1 
    PGY2 
    PGY3 
    Faculty 
 
4.1(2.7-6.1) 
2.9 (2.0-4.3) 
3.8 (2.6-5.9) 
Referent 
Age 
  <40 
  41-50 
  51-60 
  61-70 
  >71 
 
3.1 (1.5-6.2) 
3.0 (1.8-4.9) 
2.7(1.8-4.0) 
2.2(1.5-3.3) 
Referent 
Sex 
  Female 
  Male 
 
0.7 (0.5-0.9) 
Referent 
Insurance Status  
  No cover 
  CMS 
  Private 
 
2.0(1.3-3.0) 
1.0(0.7-1.5) 
Referent 
Diabetes 
  Yes 
  No 
 
2.0 (1.1-2.2) 
Referent 
Comorbidities 
  Yes 
  No 
 
3.6 (1.5-8.4) 
Referent 
Acute Issues 
   Yes 
   No 
 
2.7 (1.9-3.8) 
Referent 
Abbreviations: 
PGY 1Postigraduate year 1 
PGY 2 Postgraduate year 2 
PGY 3 Postgraduate year 3 
Bold indicates that the findings is significant at α=0.05 (p< .05) 
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Table 4: Multivariate analysis for the costs of visits and other demographic and clinical 
characteristics for controlled hypertension 
Independent variables OR (95% CL) P-value 
Postgraduate year 
    PGY1 
    PGY2 
    PGY3 
    Faculty 
   
0.9 (0.9-1.0) 
2.4(1.9-9.0) 
0.9(0.7-1.6) 
Referent 
 
0.7 
0.001 
0.2 
Referent 
 
Age 
  <40 
  41-50 
  51-60 
  61-70 
  >71 
 
0.3 (0.1-1.3) 
0.7 (0.4-1.5) 
0.8 (0.5-1.4) 
0.9 (1.2-2.6) 
Referent 
 
0.3 
0.2 
0.8 
0.9 
Referent 
Sex 
  Female 
  Male 
 
0.2(1.0-3.0) 
Referent 
 
0.3 
Referent 
Insurance Status  
  No cover 
  CMS 
  Private 
 
0.7(0.5-1.3) 
0.3 (0.0-2.5) 
Referent 
 
 
0.2 
0.4 
Referent 
 
Diabetes 
  Yes 
  No 
 
2.0 (1.1-2.3) 
Referent 
 
0.0003 
Referent 
Comorbidities 
  Yes 
  No 
 
6.0 (1.2-20.1) 
Referent 
 
0.0002 
Referent 
Acute Issues 
   Yes 
   No 
 
4.0 (2.0-7.0) 
Referent 
 
0.001 
Referent 
 
Abbreviations: 
PGY 1Postigraduate year 1 
PGY 2 Postgraduate year 2 
PGY 3 Postgraduate year 3 
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Bold indicates that the findings are significant at α=0.05 (p< .05) 
 
